Series A · $25M Raise
Med
Nova
Therapeutics
Pioneering
AAV-based gene therapy
to deliver a one-time cure for
Friedreich's Ataxia
— a devastating disease with no disease-modifying treatments.
Boston, MA
Gene Therapy · Rare Disease · Phase I/II
March 2026